MEF2D Antibody
Shipped with Ice Packs 
In Stock 
Description
Definition and Core Characteristics
MEF2D antibodies are polyclonal or monoclonal immunoglobulin preparations that specifically bind to the MEF2D protein, a member of the MEF2 family of transcription factors. Key features include:
Key Applications in Research
These antibodies serve multiple experimental roles across biological disciplines:
Transcriptional Regulation Mechanisms
ChIP-chip analyses using MEF2D antibodies identified 182 direct target genes involved in:
Control experiments demonstrated antibody specificity through peptide antigen preabsorption, eliminating false positives in promoter binding assays .
Oncological Implications
Recent breast cancer studies revealed:
These findings position MEF2D as a tumor suppressor through its regulation of:
Disease Relevance and Therapeutic Potential
Emerging evidence demonstrates MEF2D's involvement in:
Product Specs
Buffer
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form
Liquid
Lead Time
Typically, we are able to ship orders within 1-3 business days of receipt. Delivery time may vary depending on the purchase method and location. Please consult your local distributors for specific delivery timeframes.
Synonyms
DKFZp686I1536 antibody; MADS box transcription factor 2 polypeptide D antibody; Mef2d antibody; MEF2D_HUMAN antibody; Myocyte enhancer factor 2D antibody; Myocyte specific enhancer factor 2, polypeptide D antibody; Myocyte specific enhancer factor 2D antibody; Myocyte-specific enhancer factor 2D antibody
Target Names
Uniprot No.
Target Background
Function
MEF2D Antibody is a transcriptional activator that binds specifically to the MEF2 element, 5'-YTA[AT](4)TAR-3', which is found in numerous muscle-specific, growth factor- and stress-induced genes. It mediates cellular functions not only in skeletal and cardiac muscle development, but also in neuronal differentiation and survival. MEF2D plays diverse roles in the control of cell growth, survival and apoptosis via p38 MAPK signaling in muscle-specific and/or growth factor-related transcription. It plays a critical role in the regulation of neuronal apoptosis.
Gene References Into Functions
Research References:
- Our study suggests that the MEF2D, PRDM16 and ASTN2 genes from GWAS are associated with migraine susceptibility, especially migraine without aura , among Chinese patients. It appears that there is no association with serotonin receptor related genes. PMID: 28058730
- In summary, we found that miR-1244 affected cisplatin-treated non-small cell lung cancer via MEF2D expression. PMID: 28498474
- MEF2d mRNA level is up-regulated in both sporadic and SOD1 + ALS patients. PMID: 26921792
- MEF2D might be a potential biomarker during chronic inflammation-lung cancer transition, predicting the risk of lung cancer among patients with chronic respiratory diseases. PMID: 28340574
- HIF-1alpha transactivates MEF2D expression by binding to the MEF2D gene promoter to induce angiogenesis in colorectal tumors. PMID: 28478181
- MEF2D directly regulated transcription of the epithelial-mesenchymal transition driver gene ZEB1 and facilitated histone acetylation at the ZEB1 promoter in colorectal cancer cells PMID: 27364559
- MEF2D-BCL9-positive patients had B-cell precursor immunophenotype and were characterized as being older in age, being resistant to chemotherapy, having very early relapse, and having leukemic blasts that mimic morphologically mature B-cell leukemia with markedly high expression of HDAC9. PMID: 27507882
- These results suggest that PPARgamma may exert its antiproliferative effects by negatively regulating the MEF2D in CM cells, which through upregulation of miR-122, and PPARgamma/miR-122/MEF2D signaling pathway may be a novel target for treatment of CM. PMID: 27109478
- MEF2D overexpression participated in the growth of lung cancers and its aberrant expression may result from the reduction of tumor suppressor miR-218. PMID: 26409449
- MEF2D is a direct target of miR-19. PMID: 26762410
- We found that in malignant glioma, there is an aberrantly high expression of MEF2D, which leads to poor prognosis of malignant glioma. The downregulation of MEF2D suppresses the proliferation of malignant glioma cell lines by inducing delay of S and G2/M phases of cell cycle and promoting apoptosis. PMID: 26234765
- MEF2D regulates IGF-1-induced proliferation and apoptosis in CM development, indicating IGF-1-MEF2D pathway may be a useful target for treatment. PMID: 26563368
- Pokemon was found to enhance the migration and invasion of hepatocellular carcinoma by increasing MEF2D expression PMID: 26797719
- miR-1244 and MEF2D form an autoregulatory loop contributing to the progression of lung carcinoma. PMID: 26355845
- MEF2D was also found to increase the transcription of Pokemon by binding myocyte enhancer factor 2 (MEF2) sites within its promoter region, that can promote Hepatocellular carcinoma invasion PMID: 26164003
- Cell cycle progression was also inhibited by MEF2D suppression. PMID: 25812649
- OA induced cell cycle arrest in lung cancer cells through miR-122/Cyclin G1/MEF2D pathway. This finding may contribute to the understanding of the molecular mechanism of OA's anti-tumor activity PMID: 25472877
- MEF2D suppression was shown to decrease the proliferation of osteosarcoma cells. PMID: 25814384
- Oxidation of survival factor MEF2D inhibits its function, underlies oxidative stress-induced neurotoxicity, and may be a part of the Parkinson disease pathogenic process. PMID: 24219011
- The oncogenic properties of rhabdomyosarcoma cells can be partially attributed to the loss of MEF2D expression. PMID: 24279793
- MEF2D-silencing abolished hepatocellular carcinoma tumorigenicity. PMID: 24390737
- The expression of MEF2D was higher in the higher clinical stage of nasopharyngeal carcinoma, but there was no correlation with survival rate. PMID: 22256741
- direct regulation of complex I by mitochondrial MEF2D underlies its neuroprotective effects, and dysregulation of this pathway may contribute to Parkinson disease PMID: 21393861
- data implicate MEF2D in human cancer and suggest that MEF2D/DAZAP1 and/or DAZAP1/MEF2D contribute to leukemogenesis by altering signaling pathways normally regulated by wild-type MEF2D and DAZAP1 PMID: 15744350
- histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications regulate MEF2 PMID: 16166628
- These results reveal an unexpected role for HDAC3 and suggest a novel pathway through which MEF2 activity is controlled in vivo. PMID: 17158926
- MEF2D levels were increased in the brains patients with Parkinson's disease PMID: 19119233
Database Links
Protein Families
MEF2 family
Subcellular Location
Nucleus. Note=Translocated by HDAC4 to nuclear dots.
Quick Inquiry
Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
